Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 5032
1. Matsuo T, Miyata Y, Asai A, Sagara Y, Furusato B, Fukuoka J, Sakai H: Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer. PLoS One; 2017;12(1):e0171091
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer.
  • Green tea polyphenol (GTP) suppresses carcinogenesis and aggressiveness in many types of malignancies including bladder cancer.
  • [MeSH-major] Polyphenols / pharmacology. Tea / chemistry. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Life Sci. 2013 Sep 3;93(8):307-12 [23871988.001]
  • [Cites] DNA Cell Biol. 2003 Mar;22(3):217-24 [12804120.001]
  • [Cites] J Biol Chem. 2006 Nov 3;281(44):33761-72 [16950787.001]
  • [Cites] PLoS One. 2013;8(3):e59095 [23516604.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1234-40 [16424063.001]
  • [Cites] Vasc Cell. 2013 May 02;5(1):9 [23638734.001]
  • [Cites] J Nutr. 2002 Aug;132(8):2307-11 [12163680.001]
  • [Cites] Urol Int. 2013;90(1):10-6 [23052791.001]
  • [Cites] Oncotarget. 2015 Sep 29;6(29):27312-31 [26314962.001]
  • [Cites] Cancer Epidemiol. 2010 Jun;34(3):350-4 [20362526.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2217-24 [15358631.001]
  • [Cites] Biochem Pharmacol. 2011 Dec 15;82(12):1807-21 [21827739.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):844-50 [11259102.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1741-9 [12738729.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6959-63 [18056170.001]
  • [Cites] Urology. 2011 Aug;78(2):476.e9-15 [21696810.001]
  • [Cites] Cancer Lett. 2001 Jun 26;167(2):175-82 [11369139.001]
  • [Cites] Mol Cell Biol. 2009 May;29(10 ):2622-35 [19289500.001]
  • [Cites] Cancer Res Treat. 2009 Jun;41(2):87-92 [19707506.001]
  • [Cites] Cancer Epidemiol. 2015 Dec;39 Suppl 1:S84-92 [26164655.001]
  • [Cites] Rev Urol. 2006 Winter;8(1):8-13 [16985555.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 23;354(4):852-7 [17266926.001]
  • [Cites] Sci Rep. 2015 Mar 12;5:9051 [25761588.001]
  • [Cites] Tumour Biol. 2015 Jan;36(1):315-27 [25252849.001]
  • [Cites] Biomed Res. 2009 Aug;30(4):207-15 [19729851.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2015 Sep;117(3):164-72 [25625183.001]
  • [Cites] Transl Res. 2014 Dec;164(6):468-76 [25063314.001]
  • [Cites] Clin Nutr. 2013 Dec;32(6):894-903 [23582951.001]
  • [Cites] Anticancer Res. 2014 Feb;34(2):735-44 [24511007.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):558-68 [17406000.001]
  • [Cites] Life Sci. 2006 Nov 17;79(25):2329-36 [16945390.001]
  • [Cites] J Neurooncol. 2008 Jun;88(2):143-55 [18317686.001]
  • [Cites] Biochem Biophys Res Commun. 2012 Nov 2;427(4):725-30 [23036202.001]
  • [Cites] Med Oncol. 2011 Dec;28 Suppl 1:S577-85 [21046284.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1516-22 [26215293.001]
  • [Cites] Am J Transl Res. 2016 Feb 15;8(2):578-87 [27158349.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):800-6 [16467091.001]
  • [Cites] Tumour Biol. 2016 Apr;37(4):4373-82 [26499783.001]
  • [Cites] Mol Cancer Res. 2011 May;9(5):648-59 [21498545.001]
  • [Cites] PLoS One. 2011;6(10):e25224 [22022384.001]
  • [Cites] Nutr Cancer. 2014;66(2):315-24 [24447094.001]
  • [Cites] J Gastroenterol. 2014 Apr;49(4):692-701 [23543313.001]
  • [Cites] Oncol Rep. 2015 Jun;33(6):2972-80 [25845434.001]
  • [Cites] Int J Cancer. 1997 Jan 27;70(3):255-8 [9033623.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1277-84 [17081606.001]
  • (PMID = 28141864.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ELAV-Like Protein 1; 0 / Polyphenols; 0 / Tea
  •  go-up   go-down


2. Fazly Bazzaz BS, Sarabandi S, Khameneh B, Hosseinzadeh H: Effect of Catechins, Green tea Extract and Methylxanthines in Combination with Gentamicin Against Staphylococcus aureus and Pseudomonas aeruginosa: - Combination therapy against resistant bacteria. J Pharmacopuncture; 2016 Dec;19(4):312-318

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Catechins, Green tea Extract and Methylxanthines in Combination with Gentamicin Against Staphylococcus aureus and Pseudomonas aeruginosa: - Combination therapy against resistant bacteria.
  • Green tea catechins, the major green tea polyphenols, show antimicrobial activity against resistant pathogens.
  • The present study aimed to investigate the effect of catechins, green tea extract, and methylxanthines in combination with gentamicin against standard and clinical isolates of <i>Staphylococcus aureus</i> (<i>S. aureus</i>) and the standard strain of <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>).
  • The interactions of green tea extract, epigallate catechin, epigallocatechin gallate, two types of methylxanthine, caffeine, and theophylline with gentamicin were studied <i>in vitro</i> by using a checkerboard method and calculating the fraction inhibitory concentration index (FICI).
  • Green tea extract showed insufficient antibacterial activity when used alone.
  • When green tea extract and catechins were combined with gentamicin, the MIC values of gentamicin against the standard strains and a clinical isolate were reduced, and synergistic activities were observed (FICI < 1).
  • CONCLUSION: The results of the present study revealed that green tea extract and catechins potentiated the antimicrobial action of gentamicin against some clinical isolates of <i>S. aureus</i> and standard <i>P. aeruginosa</i> strains.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Soc Trans. 2012 Dec 1;40(6):1438-42 [23176495.001]
  • [Cites] Expert Opin Drug Saf. 2012 Mar;11(2):221-33 [22074343.001]
  • [Cites] Food Chem. 2012 Nov 15;135(2):672-5 [22868144.001]
  • [Cites] Adv Pharm Bull. 2012;2(2):259-63 [24312803.001]
  • [Cites] Clin Microbiol Infect. 2009 Apr;15(4):341-6 [19431221.001]
  • [Cites] Drug Dev Ind Pharm. 2015 Jun;41(6):989-94 [24842547.001]
  • [Cites] FEMS Microbiol Lett. 1997 Jul 1;152(1):169-74 [9228784.001]
  • [Cites] BMC Microbiol. 2014 Jun 27;14:172 [24969489.001]
  • [Cites] FASEB J. 2003 Oct;17(13):1913-5 [12897059.001]
  • [Cites] Braz J Microbiol. 2014 Jan 15;44(3):709-15 [24516437.001]
  • [Cites] Acta Microbiol Immunol Hung. 2012 Mar;59(1):13-20 [22510283.001]
  • [Cites] Iran J Basic Med Sci. 2015 Jan;18(1):2-7 [25810869.001]
  • [Cites] Microb Pathog. 2016 Apr;93:83-7 [26602814.001]
  • [Cites] Medicine (Baltimore). 1978 Mar;57(2):179-95 [202836.001]
  • [Cites] Food Sci Technol Bull. 2005;2:71-81 [19844590.001]
  • [Cites] Microb Pathog. 2016 Jun;95:32-42 [26911646.001]
  • [Cites] Pharmacognosy Res. 2011 Oct;3(4):266-72 [22224051.001]
  • [Cites] Iran J Basic Med Sci. 2014 Dec;17(12):929-38 [25859296.001]
  • [Cites] Nihon Saikingaku Zasshi. 1989 Jul;44(4):669-72 [2677434.001]
  • [Cites] J Basic Clin Pharm. 2014 Dec;6(1):35-9 [25538470.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Jul;46(7):2266-8 [12069986.001]
  • [Cites] Future Microbiol. 2007 Jun;2(3):323-34 [17661706.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Nov;39(11):2375-7 [8585711.001]
  • [Cites] Phytother Res. 2009 Apr;23(4):460-6 [19107860.001]
  • [Cites] Arch Pharm Res. 2011 Jan;34(1):3-21 [21468910.001]
  • [Cites] Antimicrob Agents Chemother. 2013 Mar;57(3):1421-7 [23295934.001]
  • (PMID = 28097041.001).
  • [ISSN] 2093-6966
  • [Journal-full-title] Journal of pharmacopuncture
  • [ISO-abbreviation] J Pharmacopuncture
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Keywords] NOTNLM ; Pseudomonas aeruginosa / Staphylococcus aureus / catechins / gentamicin / methylxanthine / antimicrobial resistant
  •  go-up   go-down


3. Singhal K, Raj N, Gupta K, Singh S: Probable benefits of green tea with genetic implications. J Oral Maxillofac Pathol; 2017 Jan-Apr;21(1):107-114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probable benefits of green tea with genetic implications.
  • Tea is produced from the <i>Camellia sinensis</i> plant and can generally be divided into categories based on how they are processed.
  • In general, green tea that is unfermented <i>C. sinensis</i> has been considered superior to black tea in health benefits.
  • Oral cavity oxidative stress and inflammation, consequent cigarettes due to nicotine and acrolein, may be reduced in the presence of green tea polyphenols.
  • In addition, green tea polyphenols can close down halitosis through modification of odorant sulfur components.
  • Usually, green tea defends healthy cells from malignant transformation and locally has the ability to induce apoptosis in oral cancer cells.
  • In unison, there is an increasing implication in the health benefits of green tea in the field of oral health.
  • This review will cover recent findings on the therapeutic properties and anticancer health benefits of green tea.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Nutr. 2006 Apr;25(2):79-99 [16582024.001]
  • [Cites] Eur J Oral Sci. 2010 Apr;118(2):145-50 [20487003.001]
  • [Cites] Food Chem Toxicol. 1997 Aug;35(8):827-33 [9350228.001]
  • [Cites] J Periodontol. 2009 Mar;80(3):372-7 [19254120.001]
  • [Cites] Br J Nutr. 2009 Dec;102(12):1790-802 [19751534.001]
  • [Cites] Molecules. 2007 May 03;12(5):946-57 [17873830.001]
  • [Cites] J Altern Complement Med. 2005 Jun;11(3):521-8 [15992239.001]
  • [Cites] Eur J Clin Nutr. 1996 Jan;50(1):28-32 [8617188.001]
  • [Cites] Nutrition. 2002 May;18(5):443-4 [11985958.001]
  • [Cites] Caries Res. 1999 Nov-Dec;33(6):441-5 [10529529.001]
  • [Cites] Arch Oral Biol. 2012 May;57(5):429-35 [22226360.001]
  • [Cites] J Periodontal Res. 2002 Dec;37(6):433-8 [12472837.001]
  • [Cites] Anticancer Agents Med Chem. 2006 Sep;6(5):389-406 [17017850.001]
  • [Cites] J Periodontal Res. 2004 Oct;39(5):300-7 [15324350.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4524-9 [10200295.001]
  • [Cites] Biol Psychiatry. 2007 Dec 15;62(12):1353-62 [17624318.001]
  • [Cites] J Periodontol. 1993 Jul;64(7):630-6 [8396176.001]
  • [Cites] Am J Clin Nutr. 2007 Oct;86(4):1243-7 [17921409.001]
  • [Cites] BMC Complement Altern Med. 2014 Aug 30;14:322 [25175005.001]
  • [Cites] Arch Intern Med. 2003 Jun 23;163(12):1448-53 [12824094.001]
  • [Cites] Antiviral Res. 2003 Apr;58(2):167-73 [12742577.001]
  • [Cites] J Indian Soc Periodontol. 2012 Apr;16(2):161-7 [23055579.001]
  • [Cites] J Cell Biochem. 2001;82(3):387-98 [11500915.001]
  • [Cites] Cancer Lett. 1998 Jul 17;129(2):173-9 [9719459.001]
  • [Cites] Arch Biochem Biophys. 2000 Apr 15;376(2):338-46 [10775421.001]
  • [Cites] Int J Cardiol. 2006 Apr 14;108(3):301-8 [15978686.001]
  • [Cites] J Periodontal Res. 2010 Feb;45(1):23-30 [19602116.001]
  • [Cites] Explore (NY). 2006 Nov-Dec;2(6):531-9 [17113495.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):6009-14 [12719524.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2008 Mar;18(2):158-66 [17410113.001]
  • [Cites] Oral Microbiol Immunol. 2004 Apr;19(2):118-20 [14871352.001]
  • [Cites] Biochem Pharmacol. 1999 Sep 15;58(6):911-5 [10509743.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 22;292(1):94-101 [11890677.001]
  • [Cites] Biosci Biotechnol Biochem. 1996 May;60(5):745-9 [8704303.001]
  • [Cites] J Med Chem. 2007 Jan 25;50(2):264-71 [17228868.001]
  • [Cites] Rev Saude Publica. 2004 Feb;38(1):100-5 [14963548.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):1968-73 [15155186.001]
  • [Cites] Antiviral Res. 1993 Aug;21(4):289-99 [8215301.001]
  • [Cites] Ann N Y Acad Sci. 2001 Apr;928:274-80 [11795518.001]
  • [Cites] J Oral Pathol Med. 2007 Nov;36(10):588-93 [17944751.001]
  • [Cites] Ann Nutr Metab. 2004;48(2):95-102 [14988639.001]
  • [Cites] Clin Nutr. 2006 Oct;25(5):790-6 [16698148.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Apr;220(4):218-24 [10202392.001]
  • [Cites] J Clin Aesthet Dermatol. 2012 Feb;5(2):34-41 [22468171.001]
  • [Cites] Arch Pharm Res. 1998 Jun;21(3):348-52 [9875456.001]
  • [Cites] Eur J Pharmacol. 2004 Oct 1;500(1-3):177-85 [15464031.001]
  • [Cites] Tob Induc Dis. 2003 Sep 15;1(3):219-26 [19570263.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2001 Feb;128(2):153-64 [11239828.001]
  • [Cites] Heart. 2004 Dec;90(12):1485-6 [15547040.001]
  • [Cites] J Endod. 2010 Jan;36(1):83-6 [20003940.001]
  • [Cites] Drug Metabol Drug Interact. 2004;20(1-2):43-56 [15283302.001]
  • [Cites] J Am Coll Nutr. 2002 Feb;21(1):1-13 [11838881.001]
  • [Cites] Pharmacol Res. 2011 Aug;64(2):105-12 [21624470.001]
  • [Cites] Exp Toxicol Pathol. 2005 Jul;57 Suppl 1:43-73 [16092717.001]
  • [Cites] Iran J Basic Med Sci. 2012 May;15(3):880-4 [23493325.001]
  • [Cites] J Indian Soc Periodontol. 2011 Jan;15(1):18-22 [21772716.001]
  • [Cites] J Nutr Biochem. 2004 Sep;15(9):506-16 [15350981.001]
  • [Cites] J Immunol. 2003 Apr 15;170(8):4335-41 [12682270.001]
  • [Cites] Phytother Res. 2004 Aug;18(8):624-7 [15476306.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):132-7 [14744744.001]
  • [Cites] J Agric Food Chem. 2004 Mar 24;52(6):1688-92 [15030231.001]
  • [Cites] Toxicol Sci. 2006 Feb;89(2):547-53 [16280382.001]
  • (PMID = 28479696.001).
  • [ISSN] 0973-029X
  • [Journal-full-title] Journal of oral and maxillofacial pathology : JOMFP
  • [ISO-abbreviation] J Oral Maxillofac Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Keywords] NOTNLM ; Antioxidants / Camellia sinensis / cancer / tea
  •  go-up   go-down


Advertisement
4. Megow I, Darvin ME, Meinke MC, Lademann J: A Randomized Controlled Trial of Green Tea Beverages on the in vivo Radical Scavenging Activity in Human Skin. Skin Pharmacol Physiol; 2017;30(5):225-233
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Randomized Controlled Trial of Green Tea Beverages on the in vivo Radical Scavenging Activity in Human Skin.
  • Green tea is one of the main sources of polyphenolic antioxidant compounds, but only few data are available on its cutaneous antioxidant effects.
  • METHODS: The radical scavenging properties of Benifuuki and Yabukita green tea were investigated in the human skin.
  • Thirty-two participants who met the inclusion criteria were randomized to consume 3 cups per day of either Benifuuki tea, Yabukita tea, or water (control group) for 2 weeks.
  • RESULTS: Both Yabukita and Benifuuki tea led to an increase in the radical scavenging activity of the skin by 28 and 29%, respectively, and the difference was significant when compared to the control group.
  • Benifuuki tea, previously reported to be superior in bioavailability due to a highly absorbable methylated catechin, did not prove to be more effective than the common Yabukita tea.
  • CONCLUSION: The results show that green tea enhances the radical scavenging capacity of the skin and support the hypothesis that green tea may offer protection against cutaneous oxidative stress.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28723689.001).
  • [ISSN] 1660-5535
  • [Journal-full-title] Skin pharmacology and physiology
  • [ISO-abbreviation] Skin Pharmacol Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Antioxidants  / Electron paramagnetic resonance spectroscopy / Free radicals / Green tea / Oxidative stress / Polyphenols / Resonance Raman spectroscopy
  •  go-up   go-down


5. Schroeder AC, Xiao H, Zhu Z, Li Q, Bai Q, Wakefield MR, Mann JD, Fang Y: A Potential Role for Green Tea as a Radiation Sensitizer for Prostate Cancer. Pathol Oncol Res; 2017 Nov 03;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Potential Role for Green Tea as a Radiation Sensitizer for Prostate Cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29101735.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Green tea / Prostate cancer / Radiation therapy
  •  go-up   go-down


6. Nejabat M, Reza SA, Zadmehr M, Yasemi M, Sobhani Z: Efficacy of Green Tea Extract for Treatment of Dry Eye and Meibomian Gland Dysfunction; A Double-blind Randomized Controlled Clinical Trial Study. J Clin Diagn Res; 2017 Feb;11(2):NC05-NC08

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of Green Tea Extract for Treatment of Dry Eye and Meibomian Gland Dysfunction; A Double-blind Randomized Controlled Clinical Trial Study.
  • Green tea extract has anti-oxidative, anti-bacterial, anti-androgen, and immunomodulatory properties.
  • AIM: To evaluate the efficacy of green tea extract for treatment of patients with dry eye and Meibomian Gland Dysfunction (MGD).
  • Topical green tea extract was prescribed three times a day for one month in one of the groups.
  • RESULTS: The mean age of participants in the green tea and control group was 61 and 64 years respectively.
  • In the green tea group, the mean score of clinical symptoms was 9±0.86 that improved to 4.86±0.55 after one month (p=0.002).
  • Scores suggesting improvement of TBUTs and the health of meibomian glands were significantly higher in the green tea group (p=0.002).
  • CONCLUSION: Green tea extract is an effective, safe, and well-tolerated topical treatment for mild and moderate evaporative dry eyes and MGD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1917-21 [21450912.001]
  • [Cites] Korean J Ophthalmol. 2007 Dec;21(4):232-7 [18063889.001]
  • [Cites] Obstet Gynecol. 2008 Jun;111(6):1371-9 [18515521.001]
  • [Cites] Hong Kong Med J. 2001 Dec;7(4):369-74 [11773671.001]
  • [Cites] Optom Vis Sci. 2005 Jul;82(7):594-601 [16044071.001]
  • [Cites] Korean J Ophthalmol. 2008 Sep;22(3):183-6 [18784447.001]
  • [Cites] Ocul Surf. 2016 Jul;14(3):365-76 [27224876.001]
  • [Cites] Curr Pharm Des. 2016;22(28):4470-90 [27296759.001]
  • [Cites] Arch Ophthalmol. 2000 May;118(5):615-21 [10815152.001]
  • [Cites] Mol Pharmacol. 2004 Jan;65(1):15-7 [14722232.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6665-70 [20702817.001]
  • [Cites] Mol Vis. 2011 Feb 18;17:533-42 [21364905.001]
  • [Cites] Ophthalmic Res. 2002 Jul-Aug;34(4):258-63 [12297700.001]
  • (PMID = 28384900.001).
  • [ISSN] 2249-782X
  • [Journal-full-title] Journal of clinical and diagnostic research : JCDR
  • [ISO-abbreviation] J Clin Diagn Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Anti-bacterial / Anti-oxidative / Ocular surface / Schirmer test
  •  go-up   go-down


7. Allam AA, Gabr SA, Ajarem J, Alghadir AH, Sekar R, Chow BK: GENO PROTECTIVE AND ANTI-APOPTOTIC EFFECT OF GREEN TEA AGAINST PERINATAL LIPOPOLYSACCHARIDE-EXPOSURE INDUCED LIVER TOXICITY IN RAT NEWBORNS. Afr J Tradit Complement Altern Med; 2017;14(2):166-176
Hazardous Substances Data Bank. Green tea .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GENO PROTECTIVE AND ANTI-APOPTOTIC EFFECT OF GREEN TEA AGAINST PERINATAL LIPOPOLYSACCHARIDE-EXPOSURE INDUCED LIVER TOXICITY IN RAT NEWBORNS.
  • BACKGROUND: This study aims to examine the protective effect of green tea on the disturbances in oxidative stress and apoptosis related factors, mostly produced due to perinatal lipopolysaccharide (LPS) exposure, that subsequently induces liver cell damage.
  • MATERIALS AND METHODS: Anti-free radical, Antioxidant, scavenging, geno-protective, and antiapoptotic activity of aqueous green tea extract (AGTE) were assessed against LPS-induced hepatic dysfunction in newborn-rats.
  • [MeSH-minor] Animals. Animals, Newborn. Endotoxemia / complications. Female. Liver Cirrhosis / drug therapy. Liver Cirrhosis / etiology. Maternal Exposure. Oxidative Stress / drug effects. Perinatal Care. Phytotherapy. Plant Extracts / pharmacology. Plant Extracts / therapeutic use. Polyphenols / pharmacology. Polyphenols / therapeutic use. Pregnancy. Rats, Wistar. Tea

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Toxicol Pathol. 2015 May-Jun;67(5-6):331-9 [25837382.001]
  • [Cites] Food Funct. 2013 Jan;4(1):10-8 [23037977.001]
  • [Cites] Exp Oncol. 2016 Mar;38(1):54-6 [27031721.001]
  • [Cites] J Tradit Complement Med. 2015 Jan 21;6(2):153-9 [27114938.001]
  • [Cites] Food Chem. 2016 Mar 1;194:32-45 [26471524.001]
  • [Cites] Immunol Lett. 2004 Jun 15;94(1-2):47-55 [15234535.001]
  • [Cites] Food Chem Toxicol. 2011 Oct;49(10):2594-9 [21777643.001]
  • [Cites] J Nutr. 2001 May;131(5):1560-7 [11340116.001]
  • [Cites] Circulation. 2002 Mar 12;105(10):1155-7 [11889006.001]
  • [Cites] Evid Based Complement Alternat Med. 2015;2015:161092 [26167188.001]
  • [Cites] J Nutr. 2002 Apr;132(4):785; author reply 786 [11925478.001]
  • [Cites] BMC Public Health. 2016 May 12;16:396 [27175786.001]
  • [Cites] Food Funct. 2016 Feb;7(2):1166-75 [26885714.001]
  • [Cites] Diabetes. 2005 Feb;54(2):517-26 [15677510.001]
  • [Cites] J Ethnopharmacol. 2010 Sep 15;131(2):478-84 [20637853.001]
  • [Cites] Food Chem Toxicol. 2012 Jun;50(6):2155-70 [22521445.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1762(4):468-77 [16497487.001]
  • [Cites] Mol Aspects Med. 2000 Jun;21(3):49-98 [10978499.001]
  • [Cites] Indian J Pediatr. 2007 Jul;74(7):663-71 [17699976.001]
  • [Cites] Eur J Nutr. 2010 Jun;49(4):227-34 [19851801.001]
  • [Cites] Exp Ther Med. 2015 Mar;9(3):787-794 [25667629.001]
  • [Cites] Trends Mol Med. 2009 Feb;15(2):50-8 [19162549.001]
  • [Cites] J Immunol. 2016 Apr 1;196 (7):3135-47 [26936883.001]
  • [Cites] Molecules. 2008 Mar 06;13(3):581-94 [18463567.001]
  • (PMID = 28573233.001).
  • [ISSN] 2505-0044
  • [Journal-full-title] African journal of traditional, complementary, and alternative medicines : AJTCAM
  • [ISO-abbreviation] Afr J Tradit Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Lipopolysaccharides; 0 / Plant Extracts; 0 / Polyphenols; 0 / Tea; 9007-49-2 / DNA
  • [Keywords] NOTNLM ; apoptosis / green tea / lipopolysaccharide / liver dysfunction / newborns
  •  go-up   go-down


8. Hammad FT, Lubbad L: The effect of epigallocatechin-3-gallate on the renal dysfunction in the obstructed kidney in the rat. Int J Physiol Pathophysiol Pharmacol; 2017;9(4):119-126
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Epigallocatechin-3-gallate (EGCG) is the most active catechin polyphenol extracted from the green tea.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplant Proc. 2006 Sep;38(7):2190-4 [16980039.001]
  • [Cites] Life Sci. 2013 Sep 3;93(8):307-12 [23871988.001]
  • [Cites] Curr Urol Rep. 2005 Mar;6(2):140-5 [15717973.001]
  • [Cites] BMC Neurosci. 2011 Jun 01;12:52 [21627848.001]
  • [Cites] J Neurotrauma. 2015 Feb 1;32(3):170-84 [25025489.001]
  • [Cites] Urol Res. 2011 Oct;39(5):351-6 [21190019.001]
  • [Cites] Urol Res. 2002 Sep;30(4):223-6 [12202939.001]
  • [Cites] J Clin Invest. 1980 Feb;65(2):400-12 [7356687.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Apr;292(4):R1456-64 [17170233.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2473-83 [16760447.001]
  • [Cites] Int Urol Nephrol. 2015 Aug;47(8):1429-35 [26122117.001]
  • [Cites] Environ Health Perspect. 1976 Jun;15:55-71 [1001297.001]
  • [Cites] Transpl Int. 2011 May;24(5):514-22 [21291499.001]
  • [Cites] Evid Based Complement Alternat Med. 2012;2012:845917 [22844338.001]
  • [Cites] Pharmacol Res. 2013 Jan;67(1):68-78 [23103594.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 2):F766-72 [10564241.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Dec;287(6):F1283-93 [15328069.001]
  • [Cites] Curr Med Chem. 2004 Jun;11(11):1375-89 [15180572.001]
  • [Cites] Eur Surg Res. 2011;46(4):188-93 [21474940.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2015 Sep;117(3):164-72 [25625183.001]
  • [Cites] Clin Nutr. 2013 Dec;32(6):894-903 [23582951.001]
  • [Cites] Kidney Int. 2000 Jul;58(1):242-50 [10886569.001]
  • [Cites] J Am Soc Nephrol. 2003 Oct;14 (10 ):2534-43 [14514731.001]
  • [Cites] Int Urol Nephrol. 2014 Apr;46(4):765-76 [24072452.001]
  • [Cites] J Cell Physiol. 2013 May;228(5):917-24 [23086807.001]
  • [Cites] Kidney Int. 1985 Oct;28(4):614-20 [4087683.001]
  • [Cites] Am J Physiol. 1986 Feb;250(2 Pt 2):F282-7 [3456211.001]
  • [Cites] Mol Med Rep. 2013 Apr;7(4):1096-102 [23358654.001]
  • [Cites] J Clin Invest. 1945 May;24(3):388-404 [16695228.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Apr;220(4):234-8 [10202395.001]
  • [Cites] Exp Mol Pathol. 2009 Apr;86(2):114-20 [19118545.001]
  • [Cites] Br J Pharmacol. 2013 Mar;168(5):1059-73 [23072320.001]
  • [Cites] J Histochem Cytochem. 2015 Apr;63(4):270-9 [25549657.001]
  • [Cites] Dig Dis Sci. 2014 May;59(5):976-85 [24318805.001]
  • [Cites] J Surg Res. 2015 Jul;197(1):145-54 [25913488.001]
  • [Cites] Br J Nutr. 2008 Sep;100(3):652-9 [18252021.001]
  • (PMID = 28951774.001).
  • [ISSN] 1944-8171
  • [Journal-full-title] International journal of physiology, pathophysiology and pharmacology
  • [ISO-abbreviation] Int J Physiol Pathophysiol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Epigallocatechin-3-gallate / renal functions / ureteral obstruction
  •  go-up   go-down


9. Roomi MW, Kalinovsky T, Niedzwiecki A, Rath M: Modulation of MMP-2 and -9 secretion by cytokines, inducers and inhibitors in human melanoma A-2058 cells. Oncol Rep; 2017 Jun;37(6):3681-3687

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At near confluence, the cells were washed with PBS and incubated in serum-free media with phorbol 12-myristate 13-acetate (PMA) at 10, 25, 50 and 100 ng/ml; TNF-α and IL-1β at 0.1, 1, 10 and 25 ng/ml; LPS at 10, 25, 50 and 100 µg/ml; epigallocatechin gallate (EGCG) and doxycycline (Dox) at 10, 25, 50 and 100 µM without and with PMA; a nutrient mixture (NM) containing lysine, proline, ascorbic acid and green tea extract without and with PMA at 10, 50, 100, 500 and 1,000 µg/ml; actinomycin D and cyclohexamide at 2 and 4 µM; retinoic acid and dexamethasone at 50 µM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28440509.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Rashidi B, Malekzadeh M, Goodarzi M, Masoudifar A, Mirzaei H: Green tea and its anti-angiogenesis effects. Biomed Pharmacother; 2017 May;89:949-956

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Green tea and its anti-angiogenesis effects.
  • Green tea (from the Camellia sinensis plant) is one of the most popular beverages in the world.
  • Green tea and its polyphenolic substances (like catechins) show chemo-preventive and chemotherapeutic features in various types of cancer and experimental models for human cancers.
  • The tea catechins, including (-)-epigallocatechin-3-gallate (EGCG), have multiple effects on the cellular proteome and signalome.
  • Note that the polyphenolic compounds from green tea are able to change the miRNA expression profile associated with angiogenesis in various cancer types.
  • This review focuses on the ability of the green tea constituents to suppress angiogenesis signaling and it summarizes the mechanisms by which EGCG might inhibit the VEGF family.
  • We also highlighted the miRNAs affected by green tea which are involved in anti-angiogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Masson SAS. All rights reserved.
  • (PMID = 28292023.001).
  • [ISSN] 1950-6007
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Keywords] NOTNLM ; Angiogenesis / Epigallocatechin-3-gallate / Green tea / MicroRNA / VEGF
  •  go-up   go-down






Advertisement